Quantitative Susceptibility Mapping (QSM): Decoding MRI Data for a Tissue Magnetic Biomarker

Yi Wang1,2,3,* and Tian Liu4

In MRI, the main magnetic field polarizes the electron cloud of a molecule, generating a chemical shift for observer protons within the molecule and a magnetic susceptibility inhomogeneity field for observer protons outside the molecule. The number of water protons surrounding a molecule for detecting its magnetic susceptibility is vastly greater than the number of protons within the molecule for detecting its chemical shift. However, the study of tissue magnetic susceptibility has been hindered by poor molecular specificities of hitherto used methods based on MRI signal phase and T2* contrast, which depend convolutedly on surrounding susceptibility sources. Deconvolution of the MRI signal phase can determine tissue susceptibility but is challenged by the lack of MRI signal in the background and by the zeroes in the dipole kernel. Recently, physically meaningful regularizations, including the Bayesian approach, have been developed to enable accurate quantitative susceptibility mapping (QSM) for studying iron distribution, metabolic oxygen consumption, blood degradation, calcification, demyelination, and other pathophysiological susceptibility changes, as well as contrast agent biodistribution in MRI. This paper attempts to summarize the basic physical concepts and essential algorithmic steps in QSM, to describe clinical and technical issues under active development, and to provide references, codes, and testing data for readers interested in QSM. Magn Reson Med 73:82–101, 2015. © 2014 The Authors. Magnetic Resonance in Medicine Published by Wiley Periodicals, Inc. on behalf of International Society of Magnetic Resonance in Medicine. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited.

Key words: QSM; quantitative susceptibility mapping; gradient echo; metabolism; iron; oxygen consumption; ferritin; hemoglobin; hemorrhage; calcification; myelin; contrast agent; quantification; dipole field; dipole kernel; morphology enabled dipole inversion; Bayesian

INTRODUCTION

Magnetic susceptibility is one of the following major categories of tissue contrast mechanisms in proton MRI (1): 1) spin thermal relaxation in a voxel of water; 2) water motion, including diffusion, perfusion, flow and tissue deformation; and 3) molecular electron cloud polarization by the main magnetic field \( B_0 \). A polarized molecule generates its own magnetic field, which is known as a chemical-shift shielding field for observer protons inside the molecule and as a magnetic-susceptibility inhomogeneity field for observer protons outside the molecule. This field adds phase accumulation and consequently causes intravoxel dephasing or magnitude T2* decay in the commonly available gradient echo (GRE) MRI. Therefore, noninvasive MRI is well suited for investigating the magnetic susceptibility of tissue. The GRE phase is equal to the magnetic field multiplied by the gyromagnetic ratio \( \gamma \) and the echo time (TE). This phase may be used to further attenuate the signal for enhancing T2* image contrast, which is called susceptibility weighted imaging (2–4). However, the field at an observer location is the sum of contributions from all surrounding magnetic susceptibility sources, with each contribution dependent on the source-observer distance and orientation (5). Consequently, the phase or T2* contrast does not exclusively depict the local tissue magnetic property but is a weighted summation of the magnetic properties of the surrounding tissue, reflecting only the “shadow” of the surrounding susceptibility sources. For example, the phase and T2* contrast of tissues with weak susceptibility may primarily come from nearby air-tissue interfaces, across which there are large susceptibility changes. To uncover local tissue magnetic properties, the field has to be deconvolved, which is referred to as quantitative susceptibility mapping (QSM).

QSM was contemplated at the early days of MRI (6). However, the inversion from field to susceptibility is ill-posed (7,8): There are zeroes in the kernel connecting the susceptibility distribution and the field, and a simple kernel division causes large errors that present as streaking artifacts in the reconstructed susceptibility map (9,10). Regularization or conditioning is necessary to select a unique solution for a given field (10–16). Fortunately, MRI provides plenty of information on tissue anatomical structures. This information can serve as a prior in Bayesian regularization to overcome this ill-posed inverse problem, generating a reasonably accurate susceptibility map (17–20). Various regularizations have since been developed (17,19–30), making QSM a feasible tool for the MRI community.

As indicated by a PubMed search of QSM papers (6 in 2011; 18 in 2012; and 37 in 2013), there is rapidly growing interest in developing techniques for QSM data acquisition.
and processing, and in developing clinical and scientific applications ranging from iron distribution and metabolic consumption of oxygen to myelin in white matter (WMI) tracts (Fig. 1). This review tries to serve these interests by summarizing the basic physical concepts in QSM, outlining the fundamental algorithmic steps in QSM, organizing the available MATLAB (MathWorks, Natick, MA) codes for QSM algorithms, and surveying the clinical and technical QSM issues that are under active development.

Preparation: Estimating Susceptibility-Generated Field from its Effects on MRI Signal

In the MRI main field $B_0$, a molecule in tissue gains a magnetic moment $\mathbf{p}$ through its electron cloud polarization. Correspondingly, a tissue with volume magnetic susceptibility $\chi$ gains magnetization $\mathbf{m}(r) \approx \chi(r)B_0/\mu_0$ (see TISSUE MAGNETISM in supporting information for a brief summary of the molecular physics). Tissue magnetization generates its own magnetic field that affects MRI signal. Here we review the mathematical relationships that link magnetization, field, and MRI signal, based on which the field can be estimated from the MRI signal.

Magnetic Dipole Field and Field Observed by a Proton in Tissue

According to Maxwell’s equations in vacuum, a magnetic dipole moment $\mathbf{p}$ at a source location $\mathbf{r}'$ generates a magnetic field $\mathbf{b}(r)$ at an observation location $\mathbf{r}$ (5) ($\partial_{\mathbf{r}'}$ is a unit vector along $\mathbf{r} - \mathbf{r}'$):

$$\mathbf{b}(\mathbf{r}) = \frac{\mu_0}{4\pi} \int_{\mathbf{r} \neq \mathbf{r}'} \frac{3(\mathbf{m}(\mathbf{r}')\cdot \partial_{\mathbf{r}'})\partial_{\mathbf{r}'} - \mathbf{p}}{|\mathbf{r} - \mathbf{r}'|^3} \mathrm{d}^3\mathbf{r}' + \frac{2\mu_0}{3} \mathbf{p}_0 \delta(\mathbf{r} - \mathbf{r}') \quad \text{[1]}.$$  

Here, the inverse-cube of the distance term characterizes the spatial extent of the dipole field. The delta-function term can be understood from the field of a current loop with a fixed magnetic moment and a radius $\to 0$ (Fig. 2). In water MRI, the delta-function term is dropped; the probability of the polarized electron cloud penetrating into the space of the observer water protons is negligible. Thus, the field (scaled to $B_0$) observed by a water proton is the sum of contributions from all surrounding susceptibility sources [their distribution defined by magnetization $\mathbf{m}(\mathbf{r})$], excluding that from the proton’s own location:

$$\mathbf{b}(\mathbf{r}) = \frac{\mu_0}{4\pi} \int_{|\mathbf{r} - \mathbf{r}'| > \delta} \frac{3\mathbf{m}(\mathbf{r}')\partial_{\mathbf{r}'} - \mathbf{p}}{|\mathbf{r} - \mathbf{r}'|^3} \mathrm{d}^3\mathbf{r}' - \frac{2\mu_0}{3} \mathbf{p}_0 \delta(\mathbf{r} - \mathbf{r}') \quad \text{[2]}.$$  

The exclusion of the observer point in the integration of Eq. [2] represents the Cauchy principal value, commonly known as the Lorentz correction. This is conventionally, but unnecessarily, interpreted as subtracting a sphere of magnetization $\mathbf{m}$ that has a uniform interior field $\mu_0 \mathbf{p}_0 / 3$ from the sum of the fields of all sources according to Eq. 1 (5). In Eq. [2],

$$\mathbf{d}(\mathbf{r}, \mathbf{r}') = \frac{3\mathbf{m}(\mathbf{r}')\partial_{\mathbf{r}'} - \mathbf{p}}{4\pi |\mathbf{r} - \mathbf{r}'|^3} \quad (\mathbf{r} \neq \mathbf{r}').$$  

Here [expression] = 1 if expression is true and 0 otherwise.

Eq. [2] relates the field at $\mathbf{r}$ to the magnetization distribution over the whole space. This can be expressed in a differential form that relates the field at $\mathbf{r}$ to the magnetization located at $\mathbf{r}$ (31):

$$\nabla^2 \mathbf{b}(\mathbf{r}) = \mu_0 (\nabla^2 \mathbf{m}(\mathbf{r}) / 3 - \nabla(\nabla \cdot \mathbf{m}(\mathbf{r}))), \quad \mathbf{r} \in \mathbb{R}^3 \quad \text{[3]}.$$  

Eq. [3] can be Fourier transformed into $\mathbf{B}(\mathbf{k}) = \mu_0 (\mathbf{m}(\mathbf{r}) / 3 - \mathbf{k} \cdot \mathbf{m}(\mathbf{r}) \mathbf{k}/k^2)$. For notational convenience, we use lower case for $\mathbf{r}$-space quantities and upper case for corresponding $\mathbf{k}$-space quantities (except constant $B_0$), the $z$-component ($\mathbf{m}(\mathbf{r})$) of $\mathbf{d}(\mathbf{r})$ is referred to as the dipole kernel $d(r) = 1 / (4\pi |\mathbf{r}|^3) \delta(\mathbf{r})$ with Fourier transform $D(k) = F(d(r)) = (1 / 3) / k^3 |k \neq 0|$, and the $z$-component of $\mathbf{b}(\mathbf{r})$ is noted as $b(r)$. For scalar susceptibility, Eq. [2] becomes $b(r) = (d \cdot \chi)(\mathbf{r})$ with Fourier transform $B(k) = D(k) \chi(k)$.

On the other hand, the electron cloud of a molecule does penetrate into and interact with observer protons within the molecule. Consequently, electron cloud polarization by $B_0$ induces a shielding magnetic field $-\sigma(r)B_0$ (Fig. 2) (32), or chemical shift (referenced to water), that alters the field experienced by protons within the molecule: $b(r) = (d \cdot \chi)(\mathbf{r}) - \sigma(r)B_0$. Both the magnetic susceptibility (observed by a large number of water protons outside the molecule) and the chemical shift (observed by protons inside the molecule) reflect the same molecular electron-cloud polarization (33–35).

Field Effects on MRI Signal

The magnetic field of a polarized molecule may affect the MRI signal magnitude through a chemical exchange between free water and water bound to the molecule (inner sphere relaxation) and through a free water diffusion in the field (outer sphere relaxation) (36). These complicated effects are characterized as relaxation enhancement (37–41). Susceptibility estimation from MRI signal magnitude affected by relaxation is prone to large errors (31). Fortunately, the phase of a water proton spin linearly increases with the field. Using multiple radio frequency (RF) coils, with the $\alpha$th coil element having a complex coil sensitivity function $c_\alpha(r)$ and acquisition noise $N_\alpha$, the $\mathbf{k}$-space signal measured in coil $\alpha$ at time $t$ is (1):

$$S_\alpha(t) = \int c_\alpha(r) \mathbf{m}(r) e^{-i\omega_0 b(r)t} e^{-i\mathbf{k} \cdot \mathbf{r}} e^{-2\pi i k \cdot r} d^3r + N_\alpha. \quad \text{[4]}.$$  

Here, $\omega_0 = \gamma B_0$ and $\mathbf{m}(r)$ is the proton transverse magnetization ($\mathbf{m}(r)$ is proportional to proton density and is much smaller than $\mathbf{m}(r)$ the electronic magnetization). Typically, $T_2$ is homogeneous within a voxel and is much longer than the readout duration $(e^{-i\mathbf{k} \cdot \mathbf{r}}/T_2) \approx e^{2\pi k \cdot r}$, and the data sampling gradient $\frac{\partial}{\partial \mathbf{k}}$ is much larger than $\nabla b(r)$ ($e^{-i\omega_0 b(r) \mathbf{k}} \approx e^{2\pi i k \cdot r}/T_2$).

Then, the complex image $\mathbf{m}(\mathbf{r}) e^{-i\omega_0 b(r)\mathbf{TE}}$ can be reconstructed using the Moore-Penrose pseudo-inverse (1) for both full $\mathbf{k}$-space sampling (42) and parallel imaging (43). Approximating the voxel sensitivity function (44) as a box function, the signal detected at TE in a voxel centered at $\mathbf{r}$ with size $\Delta \mathbf{r}$ (volume $\Delta V$) is the summation over signals from all proton spins in the voxel.
FIG. 1. Biomedical magnetic materials. (a) Diamagnetic hemoglobin and paramagnetic deoxyhemoglobin. During metabolic consumption of oxygen in the brain, heart, and kidney, weakly diamagnetic oxyhemoglobin releases \( \text{O}_2 \) and becomes strongly paramagnetic deoxyhemoglobin. Whereas the 3d electron orbits of \( \text{Fe}^{2+} \) in deoxyhemoglobin may be approximated as an isolated iron atom with four unpaired electrons (right), the intramolecular interaction between the porphyrin ring and \( \text{Fe}^{2+} \) in oxyhemoglobin (ligand interaction) splits the Fe atom’s 3d-orbit into two levels, \( e_g \) and \( t_{2g} \), with all six electrons paired in the three \( t_{2g} \) orbits. (b) Blood degradation in hemorrhage. Following the onset of a hemorrhage, a small fraction of red blood cells (RBCs) may be endocytosed by microglia/macrophages. The majority of RBCs undergo cell lysis and hemoglobin (Hb) degradation from deoxyhemoglobin into methemoglobin (Fe\(^{3+}\)) and hemosiderin (possible magnetic domain). Modeled after: Lancet Neurol 2012;11:720–731. (c) Susceptibility sources in the human brain. Major susceptibility sources in (i) the brain include myelin and ferritin. The white matter tracts in the brain consist of myelinated nerve fibers. (ii) Zoomed view of the box in (i) showing axon (yellow) and myelin sheath (purple). Myelin consists of several layers of lipid bilayer. (iii) Zoomed view of the box in (ii) showing a lipid bilayer and an individual lipid. (iv) Ferritin in a cross-section. Ferritin consists of a peptide spherical shell 2-nm thick with a 8-nm diameter cavity. Fe\(^{3+}\) enters through a four-fold symmetric channel, is stored as Fe\(^{3+}\) oxide mineral, and is released as Fe\(^{2+}\) through a three-fold symmetric channel. There are five unpaired 3d electrons in Fe\(^{3+}\), generating strong paramagnetism.
detected with asymmetric spin echo (SE) sequences. It is possible to reduce scan time. Susceptibility effects may also be compensated for by using parallel imaging. Resolution should be as high as possible to achieve adequate signal-to-noise ratio (SNR). Flow compensation can be used to account for phases caused by motion (48). The three-dimensional (3D) GRE sequence is currently the most frequently used sequence for QSM. Multiple echoes (number of echoes $N_e = 1–12$ having been reported in literature) can be used with short TE for detecting strong susceptibility and long TEs for weak susceptibilities. The GRE sequence on a typical 3T MRI system may allow a high-resolution acquisition ($0.5 \times 0.5 \times 2.0$ mm$^3$) with minimal first TE $\sim 5$ msec, uniform TE spacing $\sim 5$ msec, readout bandwidth $\sim 300$ Hz/pixel, last TE $\sim 45$ msec, and TR $\sim 50$ msec (whole brain scan time $\sim 5–10$ min). For imaging regions with very strong susceptibility variations, such as those containing the bone-tissue and air-tissue interfaces, ultra-short (45,46) or zero TE (47) and small TE increments may be used to achieve adequate signal-to-noise ratio (SNR). Flow compensation can be used to account for phases caused by motion (48). Resolution should be as high as possible to minimize averaging effects in Eq. [5]. Parallel imaging and spiral sampling trajectories (49,50) can be used to reduce scan time. Susceptibility effects may also be detected with asymmetric spin echo (SE) sequences. It is also possible to measure the magnetic field in a voxel through direct saturation of the water protons at a range of off resonance frequencies and Lorentzian lineshape fitting (water saturation shift referencing) (51), similar to continuous-wave NMR spectroscopy. Whereas GRE sequences generally are faster than SE sequences, there may be applications that benefit from a combination of GRE and SE acquisitions.

**Digitzed Dipole Field: Field and Susceptibility Averaged over a Voxel and Localized at the Voxel Center**

The field averaged over a voxel in Eq. [5] requires digitization of Eq. [2]. The assumption that the distributions of the observation protons and susceptibility sources are fairly uniform within a voxel (physical smoothness) may allow for digital interpretation of Eq. [2]; $r$ as the voxel center, $b(r)$ as the field value at $r$, and $\chi(TE)$ as the average of the susceptibilities in the source voxel positioned at $r$. This digitization can be analytically derived for spherically shaped voxels: The field’s spherical mean value equals the field value at the sphere center (5); the field outside of a uniformly magnetized sphere is equivalent to the field of a dipole defined by the sphere’s total moment placed at the sphere’s center; and the field inside the sphere is zero (with the Lorentz correction by Eq. [2]). The physical smoothness requirement is reasonably valid for high resolution MRI, and sinc-interpolation or zero-padding (44) may be used to reduce the digitization error. Accordingly, Eq. [2] will be used to model the MRI signal with voxels indexed by $r$.

**QSM Step 0: Estimate the Total Field from MRI Data**

Eq. [5] models the MRI signal $s(r, TE)$ as a product of an exponential factor $e^{-b(r)\omega_0 TE}$ that describes a phase linear in time and a complex amplitude $a(r, TE)$ that contains a constant phase and an amplitude decay with time. Then, the total field $b(r)$ can be estimated from MRI signals at multiple TEs as a nonlinear least-squares problem per voxel (20,21,27):

$$b(r) = \arg \min \sum_{j=1}^{N_e} |s_j(r, TE_j) - a_j(r, TE_j)e^{-b_j(r)\omega_0 TE_j}|^2.$$  [6]
search method, such as the Gauss-Newton (20) or Levenberg-Marquardt method (52), with \( b(r)_{\text{w}} \) initialized as the linear rate of phase evolution between the first two echoes \( (N_e > 1) \). Eq. [6] may also be solved rapidly using autoregression (53). Interestingly, although Eq. [5] requires the estimation of complex coil sensitivity from calibration data (42,43), the field can be estimated without full knowledge of complex coil sensitivities from the phase difference at two TEs (54–57) or even at a single echo (58).

The field estimated from Eq. [6] can contain many artificial jumps from voxel to voxel because \( e^{-i\phi} \) is periodic in \( \phi \) and can only define \( \phi \) up to a period such as \([-\pi, \pi] \). Consequently, \( b(r)_{\text{w}} \) outside \([-\pi, \pi] \) is aliased or wrapped into \([-\pi, \pi] \), resulting in abrupt artificial jumps of \( J \cdot 2\pi \) \( (J \) is an integer) in the output phase, which is called the wrapped phase denoted by \( \varphi_{w} \). To estimate \( b(r) \), these phase wraps have to be compensated by adding \( J \cdot 2\pi \) as needed:

\[
b(r)_{\text{w}} \cdot TE_i = \varphi(r) = \varphi_{w}(r) + J(r) \cdot 2\pi. \tag{7}
\]

\( J(r) \) is determined by the physical consideration that the unwrapped phase is spatially continuous. Unfortunately, it is difficult to impose continuity in discrete space because discretization is an undersampled approximation of the continuous space, and noise—ubiquitous in MRI data—causes jumps in regions of low SNR. There are many algorithms to impose continuity or smoothness in phase unwrapping (59), typically via path finding (including noncontinuous path, residual balancing, or branch cut) (60) or global error minimization (least squares) (Fig. 3). Phase can also be unwrapped rapidly by the Fourier spectral solution of the Laplacian of the phase (23,61); however, second order derivatives in the Laplacian may not allow large phase changes to occur in regions with big susceptibility variations, such as near veins (62). Phase unwrapping may be avoided for field data estimated from direct water saturation lineshape (51). A frequently used method is the path-finding type, image-quality-guided region growth (63), which works robustly and rapidly on MRI data using SNR as the image-quality guidance (17,64,65).

After phase unwrapping, a few bad points with fields not consistent with Eq. [2] may remain due to turbulent flow or idiopathic causes, and their effects can be reduced using a consistency check during QSM iteration (20). As the phase measurement in MRI is relative to RF carrier frequency, the field can only be determined up to a constant uniform field, which may be removed by background field removal in the next section.

**QSM Algorithm: Formulating and Solving the Field-to-Susceptibility Inverse Problem**

The goal of QSM is to determine tissue susceptibility from the field (Eq. [6]) or the complex MRI signal (Eq. [5]) using Eq. [2], which connects the magnetic field and the tissue susceptibility. There are two fundamental challenges that are imbedded in Eq. [2] and Eq. [5], as outlined below, and we describe two QSM steps to address them correspondingly: 1) background field removal and 2) dipole inversion (Fig. 3).

**Two Fundamental Challenges in QSM**

The first fundamental challenge is the lack of MRI signal in regions with susceptibility sources. MRI signal in Eq. [5] can only be detected in the region with water or the tissue of interest \( (\Omega) \). Magnetic susceptibility sources exist outside \( \Omega \) \( (\mathbb{R}^3 \setminus \Omega) \), which is the background. However, there is no MRI signal in the background. If we regard each voxel in MRI as a field detector, then the number of detectors is less than the number of sources, making the field-to-source inverse problem ill-posed. Therefore, this lack of MRI signal in the background forms the first fundamental challenge for QSM. Susceptibility sources in tissue \( \Omega \) generate the tissue field \( b_t(r) = \mu_o \int_{\mathbb{R}^3} d(r - r') \chi(r') d^3r' \) for \( r \in \Omega \). Background susceptibility sources generate the background field \( b_b(r) = \mu_o \int_{\mathbb{R}^3 \setminus \Omega} d(r - r') \chi(r') d^3r' \) for \( r \in \Omega \). Together, they form a total field \( b(r) = b_t(r) + b_b(r) \) in tissue. \( \chi(r) \) is tissue susceptibility when \( r \in \Omega \).

The second fundamental challenge is the zero cone surface in the dipole kernel in \( r \)-space or in \( k \)-space: \( \theta = \pm 54.7^\circ \) with respect to the main magnetic
By definition, the background field \( b_b \) has no source in \( \Omega \), whereas the local tissue field \( b_t \) has sources \( \mu_0(\nabla^2 \mathbf{m}/3 - \nabla(\nabla \cdot \mathbf{m})) \) inside \( \Omega \) (Eq. [3]). From electrodynamics (5) or partial differential equation (71), for a finite domain \( \Omega \), a unique solution to Laplace’s equation Eq. [3] can be obtained according to the values at the boundary \( \partial \Omega \) (5,72). In MRI, the tissue field is typically weak. At \( \partial \Omega \), the background field may be approximated as the total field, which is the Laplacian boundary value (LBV) method (Fig. 5) to estimate background field (73).

\[
\nabla^2 b_b = 0, \quad b_b(\partial \Omega) \approx b.
\]

Eq. [8] can be solved numerically as a system of linear equations by expressing the Laplacian with a difference operator (74):

\[
\nabla^2 b_b(r) \approx \alpha_{NN} b_b(r) - b_b(r).
\]

Here, \( \alpha_{NN} \) denotes the nearest neighbor average operator. It is advantageous in SNR to express Eq. [8] using the spherical mean value (SMV) operator \( \alpha_{SMV} \) (5,70,75):

\[
\alpha_{SMV} b_b(r) - b_b(r) = 0.
\]

The system matrix is diagonally dominant (with diagonal elements = -1), and the Jacobian iterative method can be used (74) to give the \((n+1)\)th iteration solution \( b_b^{(n+1)}(r) = \alpha_{SMV} b_b^{(n)}(r) \). With an initialization \( b_b^{(0)}(r) = b(r) \) that satisfies the boundary value condition in Eq. [8], the background field can be obtained numerically by repeatedly applying \( \alpha_{SMV} \), which is the iterative spherical mean value (iSMV) method (76). However, iSMV is slow to converge. Eq. [8] can be efficiently solved using the full multi-grid solver that first finds the solution on a coarse grid and then successively refines the solution on finer grids (74).
When the boundary condition is not known, a partial differential equation in difference form may be regarded as an ill-posed problem, which can be solved by regularization. One regularization is to impose spectral truncation when evaluating the inverse Laplacian (therefore altering the inverse Laplacian).

$$\nabla^2 b_t = M_{\Omega} (\nabla^2 b), \text{ spectral truncation.} \quad [9]$$

Here, $M_{\Omega} = \{ r \in \Omega' \}$ requires $\Omega'$ is smaller by a border layer than the available tissue region $\Omega$ for computing $\nabla^2 b$. Eq. [9] can be solved as $b_t = \nabla^{-2} M_{\Omega} (\nabla^2 b)$:

$$\nabla^{-2} f = -\frac{\nabla f}{|\nabla f|^2}, \text{ using truncated singular value decomposition (TSVD) (with a carefully chosen truncation value } \lambda \text{ in } k\text{-space, and } \nabla^2 b \approx (\sigma_{SMV} - 1)b, \text{ using } \sigma_{SMV} \text{ for possible denoising benefit. This is the sophisticated harmonic artifact reduction for phase data (SHARP) [70].} \nabla^2 b \text{ in the border layer } \Omega - \Omega' \text{ may be recovered using a continuity assumption as in harmonic (background) phase removal using the Laplacian operator [HARPERELLA (62)]. Another regularization is the minimal norm of the tissue field (implicitly modifying inverse Laplacian) (62,77):

$$\nabla^2 b_t = M_{\Omega} (\nabla^2 b), \text{ min } ||b_t||_2^2. \quad [10]$$

Here, $||f||_2^2 = \sum_{r \in \Omega} |f(r)|^2$ for any field $f(r)$ (squared L2 norm). This method is called regularization-enabled SHARP (RESHARP) [77]. Eq. [10] can be expressed in a Lagrangian form $b_t (r) = \text{argmin}_{b_t} ||M_{\Omega} (\nabla^2 (b - b_t))||_2^2 + \lambda ||b_t||_2^2$.

There is another approach to estimate the background field based on the equivalent source or charge simulation method [78]. The background field can be represented by fields of dipoles outside $\Omega$ that are approximately orthogonal to the fields of dipoles inside $\Omega$ except near $\partial \Omega$. Then the background field can be estimated by all possible PDFs (17,22,69):

$$b_b = d^* \chi_0, \quad \chi_b = \text{argmin}_{\chi(b) = 0 \text{ } \forall \text{ } r \in \Omega} ||w(b - d^* \chi)||_2^2 \quad [11]$$

Here, noise-weighting $w = \sum_j T_E a_i (r, \ T_E)$ is the phase SNR, which is assumed to be large by linearizing the signal model Eq. [5]. Note that $b_b$ in tissue $\Omega$ is unique, although $\chi_b$ in background $\mathbb{R}^3 \setminus \Omega$ is not. This PDF method may provide a slight advantage in dealing with noise in $b$ by avoiding the inversion of the Laplacian in Eq. [8] through Eq. [10], and by extending to the nonlinear form, as in Eq. [6] [20]. However, the orthogonality between fields of dipoles breaks down near the boundary, making PDF prone to over-fitting errors near the border.

Because background and tissue fields are approximately orthogonal, the minimal norm of the tissue field in Eq. [10] is similar to the dominance of the background field at $\partial \Omega$ in Eq. [8], making RESHARP similar to LBV. The minimization in Eq. [10] is similar to that in Eq. [11], without noise weighting $w$, making RESHARP similar to PDF. Therefore, all four methods (LBV, SHARP, RESHARP, and PDF) based on Maxwell’s equations in Figure 5 provide similar performance, whereas there are very strong values near the tissue boundary in the HPF processed tissue field. The assumption or regularization in any method may contain errors, which propagate through into errors in the final reconstructed tissue susceptibility, a challenge for future research.

**QSM Step 2: Field-to-Susceptibility Inversion**

To address the second fundamental challenge in QSM, the ill-posedness caused by the dipole kernel zeroes, prior knowledge is again needed to uniquely identify the susceptibility component in the dipole kernel null space. For simplicity, we consider the high SNR case for which the phase noise is approximately Gaussian with variance $\alpha^2 / |a|^2$ [and we can extend to the general SNR case using the complex signal as in Eq. [6] [20]]. Then Eq. [5], after background field removal, is reduced to a linear field-to-susceptibility inverse problem (Eq. [2] with noise),

$$b(r) = (d^* \chi)(r) + n(r), \quad B(k) = D(k)X(k) + N(k). \quad [12]$$

Arbitrary susceptibility values in the dipole zero cone neighborhood $\Gamma_\alpha$ are allowed in Eq. [12]. A regularization can be used to specify susceptibility values in $\Gamma_\alpha$. Alternatively, “missing data” about the susceptibility in one orientation can be recovered by reorienting the subject in a fixed magnet and resampling the MRI signal (14,79). This method is known as the calculation of susceptibility using multiple orientation sampling (COSMOS), which delivers an exact reconstruction by fully sampling the susceptibility (14,22). Unfortunately, acquiring
multiple scans of patients in different orientations is not clinically acceptable. We should focus on the regularization approach to QSM using single orientation data.

Regularizations can be expressed in various mathematical forms including TSVD and assumptions of a smooth, sparse, or piece-wise smooth solution. Consequently, there are too many QSM methods to be characterized by a unifying framework. For the purpose of illustrating concepts, we outline two important classes of QSM methods: 1) the closed-form $k$-space approach, exemplified by TSVD based on matrix computation (80), and 2) the Bayesian approach based on optimization (52), also known as the $r$-space approach. Specific algorithm formulas, codes, and results are summarized in the next section on experimental validation. All of these solutions may suffer from model errors when the mathematical properties are not consistent with the physical reality (7,10,11,17,21,81). Additionally, noise will always propagate into the final solution.

Closed-form solutions form a class of noniterative $k$-space methods. One example is TSVD (82): 

$$X_{TSVD}(k) = \frac{|D(k)|}{|D(k)|^\lambda} B(k)$$

with $\lambda > 0$, which is similar to a Tikhonov-regularized minimal norm (MN) solution $X_{MN}(k) = \frac{|D(k)|}{|D(k)|^\lambda} B(k)$ (21,22). More commonly used in QSM is a TSVD variant called truncated $k$-space division (TKD) (10):

$$X_{TKD}(k) = \frac{\text{sgn}(D(k))}{\max(|D(k)|, \lambda)} B(k). \quad [13]$$

Truncation obviously leads to an underestimation of the susceptibility values in $\Gamma_\lambda$, and consequently produces streaking artifacts along the magic angle in the susceptibility map. This error in the TKD method is

$$X_{TKD}(k) - X(k) = \left(\frac{|D(k)|}{\max(|D(k)|, \lambda)} - 1\right) X(k) + \frac{\text{sgn}(D(k))}{\max(|D(k)|, \lambda)} N^\lambda;$$

the first part is the regularization error from points in $\Gamma_\lambda$ where the kernel has been modified by truncation; the second part is the noise error from all data points in $k$-space, but interestingly is also dominated by points in and near $\Gamma_\lambda$. The underestimation in Eq. [13] may be compensated by a scale factor (26). The streaking in Eq. [13] may be reduced using a high threshold ($\lambda = 2/3$, susceptibility-field convolving with a kernel (26) or using iterative filtering (defined by $\Gamma_\lambda$ in $k$-space) of signals outside high-susceptibility structures in $r$-space defined by a mask [iterative Susceptibility Weigted Imaging and susceptibility Mapping (iSWIM), (30)]. A variant of MN is a Tikhonov-regularized minimal gradient norm ([29]: $X_{MCN}(k) = \frac{|D(k)|}{|D(k)|^\lambda + \alpha} B(k)$).

Bayesian regularizations form a class of iterative optimization methods. To allow optimal treatment of regularization error (83), prior information is regarded as a probability distribution function (pdf) typically expressed as $\propto e^{-\lambda R(\chi)/2}$: $\lambda$ is a tunable regularization parameter and $R(\chi)$ is a functional of the susceptibility map. Noise is also characterized by its pdf. Then, the optimal solution with minimal total error from regularization and noise is the maximum a posteriori (MAP) estimate (84). For Gaussian noise with pdf $\propto e^{-|w|^2/2}$ ($w$ as in Eq. [11]) in the estimated field, the posterior probability is $e^{-\lambda R(\chi)/2} \prod L e^{-|w(x)|/2}$, the maximization of which is the MAP solution:

$$\chi(\cdot) = \text{argmin} \|w(b - d*\chi)\|^2_2 + \lambda \|M \nabla \chi\|_1. \quad [14]$$

The first term in Eq. [14] is the weighted data fidelity term, which contains noise; the second term is the regularization term, which contains the regularization error. The regularization parameter, $\lambda$, may be chosen to provide a minimal total error in a given imaging situation, and is typically chosen such that the regularization error is approximately equal to the expected noise level, a criterion known as the discrepancy principle (85–87).

There are connections between Bayesian optimization and noniterative $k$-space methods. If $w = 1$ in Eq. [14], then L2 norm-based Tikhonov regularization $R(\chi) = \|\chi\|^2_2$ leads to $X_MN(k)$ and $R(\chi) = \|\nabla \chi\|^2_2$ leads to $X_{MCN}(k)$; both are noniterative $k$-space methods. Because MRI phase noise requires spatially varying weighting $w$, noniterative $k$-space methods may suffer from noise errors (88). A wide range of forms for $R(\chi)$ in Eq. [14] have been reported, including piece-wise constant susceptibility (11,89), smooth susceptibility or susceptibility gradient (21), sparse susceptibility gradient or wavelet (21,27,90), and morphological consistency of the susceptibility map (17,19,21,25), some of which are detailed in the next section. We should note the property of the conjugate gradient method that typically is used to minimize the data fidelity term in Eq. [14] as in LSQR: The solution is initialized as zero by default, points outside the zero cone neighborhood $\Gamma_\lambda$ are calculated first (and properly) according to Krylov sequence, and later iterations fill structured noise in $\Gamma_\lambda$ that cause streaking artifacts (16,52,91) (Fig. 6). Use of a small iteration number ($n = 5$) may be regarded as an implicit regularization for a solution with moderate streaking and zero value at the $k$-space center $X(0) = 0$ (16,88). For a solver of Eq. [14] that includes use of LSQR, such as in the Gauss-Newton method, its final solution may have $X(0) = 0$. Eq. [14] may only determine the susceptibility up to a constant [similar to the Neumann boundary value problem for Laplace’s equation (5)]. Specific solvers may introduce implicit regularization in their output. A reference to water, such as the cerebrospinal fluid in the ventricles, may be used for consistent display of susceptibility values in QSM.

Available anatomic information in a specific imaging situation defines a physical prior for morphology-enabled dipole inversion (MEDI) (19,83,92). The edges in the desired susceptibility map are likely to be colocated with edges in known anatomical images, because they reflect the same anatomy. The colocalization of edges may be expressed as the sparsity of susceptibility edges outside the known edge locations using the $L_0$-norm or the more manageable $L_1$-norm (93). This minimizes streaking artifacts common to the dipole kernel null-space. From Eq. [14], one MEDI implementation to reconstruct QSM can be formulated as (17,19):

$$\chi(\cdot) = \text{argmin} \|w(b - d*\chi)\|_2^2 + \lambda \|M \nabla \chi\|_1. \quad [15]$$
Here, \( d^* \chi \) is evaluated in Fourier space by \( F^{-1}\{D(k)X(k)\} \), \( M = \|\nabla I < \tau\) for anatomic image \( I \) and threshold \( \tau \) (\( \tau \) is chosen such that approximately 30% of voxels are labeled as edges), and \( \|M\nabla X(r)\|_1 = \sum_{j \in \Omega} |M\nabla X(r)| (L_1 \text{ norm}) \). Because the dipole kernel (Fig. 4), similar to a HPF, preserves susceptibility edges in the tissue field image (5) and accordingly in the T2*-weighted (T2*w) magnitude image, the GRE magnitude (17) and phase images (25) can be used as the anatomic images. The nonlinear Eq. [15] can be solved using the Gauss-Newton method (52) without explicit formation of the memory costly inverse Hessian matrix (19). The data fidelity term in Eq. [15] can be generalized to Gaussian noise in complex data (e.g., Eq. [6]) and can be solved using a procedure identical to Eq. 15 (20).

New priors continue to be proposed; the search for the best prior is ongoing. An optimal prior may be specific to the imaging application. There has been a preliminary attempt to compare several priors (88). Multicenter trials are needed to establish a consensus on application-specific priors, which leads to the topic of the next section.

QSM Source Codes and Experimental Validations

To enable readers to try QSM algorithms on their own, here we organize the available MATLAB (MathWorks) codes for certain QSM algorithms, along with testing data (http://weill.cornell.edu/mri/pages/qsm.html). We tried to consider all the QSM methods that were published before December 1, 2013, classifying similar methods into the same category. We asked the first or corresponding authors to share MATLAB (MathWorks) codes of their methods, proofread our implementations, and comment on results of testing data, and we thank them for their valuable feedback. The page limitation forced us to select one (perhaps the most widely used) of multiple algorithms published by each group, leading to the following seven methods in Table 1: TSVD (22); TKD (10); iSWIM (30); MEDI (19); compressed sensing compensated (CSC) inversion (27); homogeneity-enabled incremental dipole inversion (HEIDI) (25); and total variation using split Bregman (TVSB) (28). The first two methods do not require anatomic prior information. The third method, iSWIM, incorporates an anatomic prior iteratively into the \( k \)-space approach. The last four methods are based on the Bayesian approach and are listed in chronologic order. The Bayesian methods all aim to minimize a function consisting of a data fidelity term in the L2 norm (measuring noise power) and a regularization term in the L1 norm or total variation (promoting

![FIG. 6. Evolution of susceptibility solutions in conjugate gradient. Susceptibility images in \( k \)-space (left column) and \( r \)-space after the first, third, fifth, 10th, and 100th iterations using the conjugate gradient solver demonstrate that the none-cone region in \( k \)-space converges quickly in the first few iterations; and the later iterations mainly contribute to signal in the cone region that manifests as streaking artifacts in the sagittal view and noise in the axial view in \( r \)-space.](image-url)

Table 1

|                | Simulated Brain | Gadolinium Phantom | In Vivo Brain |
|----------------|-----------------|-------------------|--------------|
|                | Slope          | \( R^2 \)         | Slope        | \( R^2 \)      | Slope | \( R^2 \) | Time (sec) |
| TSVD           | 0.83           | 0.83              | 0.76         | 0.99          | 0.80  | 0.45    | 1.7         |
| TKD            | 0.91           | 0.89              | 0.82         | 0.99          | 0.88  | 0.34    | 1.8         |
| iSWIM          | 0.81           | 0.82              | 0.84         | 0.99          | 0.81  | 0.48    | 14          |
| MEDI           | 0.99           | 0.99              | 0.92         | 1.00          | 0.93  | 0.59    | 1008        |
| CSC            | 0.63           | 0.65              | 0.87         | 0.99          | 0.79  | 0.60    | 3463\(^{(1)}\) |
| HEIDI          | 0.82           | 0.90              | 0.82         | 0.99          | 0.80  | 0.55    | 715\(^{(2)}\) |
| TVSB           | 0.83           | 0.94              | 0.87         | 1.00          | 0.84  | 0.42    | 40          |

All the calculations were performed on a PC equipped with Intel\(^{\text{\textregistered}}\) Core i7-3770k CPU @ 3.5 GHz and 32 GB of memory, except (1) was performed on a personal laptop with Intel Core i5-M2450 CPU @ 2.5 GHz and 8 GB of memory, and (2) was performed on a PC with Intel Core i5-2320 CPU @ 3.00 GHz and 16 GB of memory.

CPU, central processing unit; COSMOS, calculation of susceptibility using multiple orientation sampling; CSC, compressed sensing compensated; GB, gigabytes; GHz, gigahertz; HEIDI, homogeneity-enabled incremental dipole inversion; iSWIM, iterative susceptibility weighted imaging and susceptibility mapping; MEDI, morphology-enabled dipole inversion; PC, personal computer; TKD, truncated \( k \)-space division; TSVD, truncated singular value decomposition; TVSB, total variation using split Bregman.
QSM

sparsity). Whereas MEDI and HEIDI attempt to sparsify the edge difference with known anatomical priors, CSC promotes image sparsity in the wavelet domain, and TVSB hugely accelerates reconstruction speed by dropping noise whitening.

Rigorous experimental validation with a reference standard is required to assess the accuracy of any quantitative technique. This is particularly necessary for a technique involving regularization such as the QSM algorithms in Table 1. We performed three validation experiments: 1) numerical simulation with known truth, 2) MRI data of gadolinium phantom with known susceptibilities, and 3) in vivo brain MRI with susceptibilities assessed by COSMOS (92,94). These validations were imperfect, particularly because COSMOS contains errors from noise, orientation registration, and WM susceptibility anisotropy. However, they can serve as a starting point for readers to experience various QSM methods. Details of the experimental setup are described in Validation data in the supporting information. Although evaluations here are not intended to be conclusive, they allow readers to assess various QSM methods by their qualities (by examining the streaking artifacts), accuracies (by voxel-based linear regression with ground truth or reference), and computing costs (by taking the median running time of 5 consecutive runs).

The numerical simulation (Fig. S1a,b in the supporting information) demonstrated that all methods yielded satisfactory image quality, with minimal streaking in the sagittal view. The phantom experiment (Fig. S2a–c in the supporting information) demonstrated that constraining solutions' energies at the cone region alone was not sufficient to suppress streaking (TSVD, TKD). The iSWIM method reduced streaking by iterative filtering, and the most significant improvement was observed when spatial constraints were incorporated during dipole inversion (MEDI, CSC, HEIDI, TVSB). The in vivo brain MRI (Fig. 7) demonstrated that all methods successfully generated QSMs. The major structures containing high levels of ferritin (basal ganglia and nuclei in deep gray matter) or deoxyhemoglobin (veins) are shown with high paramagnetic values on QSM, and WM tracts are shown with diamagnetic values on QSM. Rapid streaking signal variations not on COSMOS were observed in TSVD and TKD, likely artifacts originating from veins. The iSWIM method reduced but did not eliminate these artifacts. TVSB overblurred compared to COSMOS; one of the causes may be its lack of noise whitening. MEDI, CSC, and HEIDI yielded QSM images similar to COSMOS.

In the accuracy assessment (Table 1), MEDI and TVSB achieved the best slope and coefficient of determination (R²) in both numerical simulation and phantom experiments, presumably because the piece-wise constant nature of the susceptibility distribution matched the assumptions in MEDI and TVSB. In the human brain, although MEDI provided the highest slope, none of the methods provided adequate R² values. A possible cause may be voxels of WM with susceptibility anisotropy. The reconstruction speed of the k-space methods were much faster than that of the iterative Bayesian methods (Table 1). However, the split Bregman implementation in

FIG. 7. Comparison of various quantitative susceptibility mapping reconstruction methods. QSM images are reconstructed using various methods from left to right and then top to bottom: TSVD, TKD, iSWIM, CSC, COSMOS, MEDI, HEIDI, TVSB, and R2* map. Most similar to COSMOS are MEDI, CSC, and HEIDI, with only very subtle differences among them: CSC has less black dots; MEDI has better defined dorsomedial nuclei of thalamus. CSC, compressed sensing compensated; COSMOS, calculation of susceptibility using multiple orientation sampling; HEIDI, homogeneity-enabled incremental dipole inversion; MEDI, morphology-enabled dipole inversion; QSM, quantitative susceptibility mapping; TKD, truncated k-space division; TSVD, truncated singular value decomposition; TVSB, total variation using split Bregman.

TVSB showed promise of fast online reconstruction for the Bayesian methods.

Clinical Applications Under Development

QSM has become sufficiently accurate for measuring the strong susceptibilities of biomaterials, including iron distribution (ferritin), in the deep brain nuclei and basal ganglia; deoxyhemoglobin in the veins; blood degradation products (hemosiderin in late stage); calcification (hydroxylapatite crystals); and exogenous species such as gadolinium. Clinical applications of QSM are being developed to probe neurodegenerative and inflammatory diseases, to assess hemorrhage, to measure metabolic consumption of oxygen, and to guide and monitor therapy. QSM can also remove blooming artifacts in traditional T2*w imaging (95), providing an accurate definition of the distribution of magnetic biomaterials in MRI. In this brief survey, we focus on neurological applications, although applications outside the brain are also promising (96).

Diamagnetic Biomaterial-Based Applications

QSM can easily differentiate diamagnetic calcification from paramagnetic materials such as hemosiderin (89,97). Both calcification and chronic hemorrhage appear hypointense on GRE magnitude images and may be undetectable on conventional T1- and T2-weighted SE imaging (98,99). GRE phase imaging has long been recognized for its ability to identify diamagnetic
calcifications (100,101), but there is no study demonstrating its diagnostic accuracy. As such, CT is widely used for detecting calcifications despite its use of ionizing radiation (102). QSM may replace CT for detecting calcification in neurocysticercosis (Fig. 8) and tumors (103–106). A clinical study demonstrated that QSM is superior to phase imaging and has a very high sensitivity (90%) and specificity (95%) for the detection of intracranial hemorrhage and calcification (97). QSM can also be used to measure the loss of myelin (107), another important diamagnetic biomaterial.

**Paramagnetic Heme Iron (Deoxyhemoglobin, Metahemoglobin, Hemosiderin)-Based Applications**

During blood degradation in hemorrhage (Fig. 1b), susceptibility progressively increases from oxyhemoglobin (diamagnetic) to deoxyhemoglobin (paramagnetic with 4 unpaired electrons in Fe$^{2+}$), methemoglobin (strongly paramagnetic with 5 unpaired electrons in Fe$^{3+}$), and hemosiderin (super paramagnetic with possible magnetic domain formation or ferromagnetic) (108–111). GRE is more sensitive than CT at detecting intracerebral hemorrhage (112,113). However, the T2* hypointensity in GRE suffers from blooming artifacts that are highly dependent on imaging parameters. Reliably estimating the hematoma volume is critical for managing hemorrhagic stroke patients (114,115), but it is difficult to do on GRE (95). QSM removes these blooming artifacts (17,19,20) and can be used as a universal measurement of microbleeds (Fig. 9) and hematoma volume in GRE MRI (111,116,117).

Susceptibility values in QSM can be converted to the venous deoxyhemoglobin concentration $[dHb]$ according to deoxyhemoglobin’s molar susceptibility $\chi_{dHb} = 10765$ ppb (48,118–120), allowing quantitative fMRI (117). The tissue metabolic rate of oxygen consumption ($MRO_2$) is regarded as a fundamental biomarker for assessing viability of aerobic tissue such as those in the brain, heart, and kidney (121). Measurements of regional blood flow $f$ by quantitative perfusion, such as the arterial spin labeling (122) and $[dHb]$ by QSM, can be used to map $MRO_2$ according to oxygen mass conservation (123–126): $MRO_2 = 4f[dHb]$. For tissues with nonheme iron such as ferritin, susceptibility contributions can be corrected using iso-metabolism manipulation (127).

**Paramagnetic Nonheme Iron (Ferritin)-Based Applications**

Iron overload can generate biologically toxic reactive oxygen species, causing oxidative stress and damaging macromolecules including proteins, lipids, and DNA (128,129). Excessive iron deposition in specific regions of the brain has been observed in many...
neurodegenerative diseases (130–133), including Parkinson’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis, Huntington’s disease, Friedreich’s ataxia, and multiple sclerosis (134–137). Consider the example of Parkinson’s disease (PD). Several studies demonstrate an increase of iron deposits in the substantia nigra in PD (138–142), perhaps increasing with disease progression (143). The abnormal increase in nigral iron generates reactive oxygen species (131), possibly causing nigrostriatal dopamine neuron degeneration (144,145) and alpha-synuclein aggregation (146,147). MRI R2* (1/T2*) has been used to measure tissue iron content (9,148–153), but R2* in a voxel reflects the field variance within that voxel (see definition after Eq. [5]). The latter depends on the background field, surrounding tissue susceptibilities, and imaging parameters including field strength, voxel size, and TE. The MRI phase has also been used to measure brain iron in PD (9,154–159), but phase is a convolution of tissue susceptibility in space (Eq. [2]). QSM overcomes the problems of R2* and phase images, enabling reliable iron quantification when there is no other substantial susceptibility contributor (90,132,133,142,160–162). Perhaps for this reason, QSM has been widely used to measure brain susceptibility (94,163).

QSM can improve visualization of the target in deep brain stimulation (DBS), the surgical implementation of stimulating electrodes in the subthalamic nuclei (STN), or the globus pallidus pars interna (GPI) for treating neurological disorders including PD (164–167). The anatomical accuracy of electrode placement is critical for a successful surgical outcome (168–176). Intraoperative CT, typically used to guide DBS, has poor contrast for the basal ganglia structures (170,172,177–181). MRI provides better tissue contrast than CT, but the visualization contrast for STN and GPI is still poor in standard T2-

FIG. 9. Quantitative susceptibility mapping for measuring paramagnetic heme iron. The total susceptibility of a cerebral microbleed measured on QSM is a physical property that is independent of TE, providing a universal measure for cerebral microbleeds burden (10 patients with 40 microbleeds). Left image panel: Microbleed appearance changes with TE (15 msec top row; 46 msec bottom row) drastically in magnitude and moderately in the R2* map but little in QSM (white arrows). Ventricle calcifications have the same sign on T2*w and R2* but opposite sign on QSM (black arrows) as microbleeds. Right graph: When TE was increased from approximately 20 to 40 msec, the measured cerebral microbleed volume increased by mean factors of 1.49 ± 0.86 (standard deviation), 1.64 ± 0.84, and 2.30 ± 1.20, respectively, for QSM, R2*, and T2*w, respectively (P <.01). However, the measured total susceptibility with QSM did not show significant change over TE (P =.31), and the variation was significantly smaller than any of the volume increases (P <.01 for each). QSM, quantitative susceptibility mapping; TE, echo time. Source: Liu et al, Radiology 2012;262:269–278.

FIG. 10. Quantitative susceptibility mapping for visualizing deep brain stimulation targets. Globus pallidus interna (GPI) and subthalamic nucleus (STN), surgical targets for deep brain stimulation, are either invisible or inseparable from surrounding tissues on T2W image (with zoom), but are clearly visualized on deep brain stimulation (QSM) (with zoom). Other basal ganglia structures well-defined on QSM include globus pallidus pars externa (GPe) and substantia nigra (SN). Source: Liu et al, Radiology 2013;269:216–23.
weighted imaging, and high field MRI using T2*w imaging has been sought for DBS (182–186). QSM can be used to remove the blurring present in T2*w and improve contrast-to-noise-ratio by C2/C10 for the visualization of the STN (160,161,187) (Fig. 10).

### Paramagnetic Contrast Agent Biodistribution Quantification-Based Application

QSM can be applied to measure the biodistribution of highly paramagnetic contrast agents (CA), providing an effective tool for quantifying CA concentration [CA] in MRI (188,189). The quantitative study of the phase change observed in contrast-enhanced MRA (190) was an initial motivation to formulate the field-to-susceptibility inverse problem (31). Absolute determination of [CA] according to T1/T2 enhancement effects requires calibration and is highly susceptible to flip angle errors (191–193). CAs with limited access to water demonstrate the well-known T1/T2 relaxation quench (191,192,194–197); relaxation enhancement requires CA binding with bound water, which, in turn, exchanges chemically with surrounding bulk water (CA→bound H2O→bulk H2O) (36,198–200) (see Supporting Figure S4). [CA] has no well-defined relationship with R2*. QSM overcomes these problems of mapping [CA] in T1/T2/T2* imaging and may be useful for determining the biodistribution of targeted CAs in molecular MRI. A high temporal-spatial gadolinium concentration Gd/C138 map can be obtained using QSM and fast imaging (201), from which quantitative perfusion map may be generated (50,202) (Fig. 11).

### Mixed Diamagnetic and Paramagnetic Applications

GRE phase images have been used to study iron distribution and demyelination in multiple sclerosis (MS) lesions (203–207). Iron distribution has been reported to be abnormally high in both the basal ganglia and lesions in MS patients (137,203,204,208,209) and may vary with lesion age and inflammatory status (204,210,211). QSM can be used to measure susceptibility changes in both lesions and nonlesion tissues in MS brains (212,213). A recent QSM study of magnetic susceptibilities of MS lesions (214) demonstrates that MS lesion susceptibilities start at the level of normal appearing WM (NAWM) (age = 0y, acute enhancing), quickly increase (within 0.5y) above that of NAWM, remain almost constant for a period (0–4y, intermediately aged and nonenhancing), and then decay gradually back to that of NAWM (> 7y).

---

**FIG. 11**: Quantitative susceptibility mapping for quantifying paramagnetic contrast agents. In an in vivo dynamic gadolinium (Gd) enhancement study of the brain, time-resolved Quantitative susceptibility mapping (QSM) was developed using spiral readout and temporal resolution acceleration with constrained evolution reconstruction (TRACER) complex image reconstruction. The difference image divided Gd molar susceptibility generates time-resolved Gd concentration map. Source: Xu et al, MRM 2014, epub.

**FIG. 12**: Quantitative susceptibility mapping for quantifying a mixture of paramagnetic and diamagnetic biomaterials. (i) Acute enhancing lesions in a 32-year-old male with RRMS at two time points: initial study (T1w+c1 and QSM1, 1st row) and 3-month follow-up (T1w+c2 and QSM2, 2nd row) (T1w+c=T1-weighted imaging with Gd). Lesions appear in the right frontal WM (white arrows) and in the lcc (black arrows). Both lesions are enhancing (arrows) on T1w+c1 and isointense (white boxes) on QSM1. The lesions changed on follow up to nonenhancing on T1w+c2 and hyperintense on QSM2 (arrows). The right frontal WM matter lesion shrunken between QSM1 and QSM2. The lcc lesion (black arrow) recovered to normal appearing on T2w and T1w (not shown), T1w+c. (ii) Nonenhancing lesions (33y, f, RRMS) on QSM at two time points (2nd row was 6 months later). All QSM lesions at time point 1 were estimated to be 1.2y using prior MRIs. All lesions (arrows) are QSM hyperintense on both time points with similar values. (iii) Chronic nonenhancing lesions (>7y, f RRMS) on QSM and T2W. Two lesions over 10 years old were detected (white arrows). They appear isointense on both QSM (white boxes, only initial study shown), lcc, left cingulate cortex; QSM, quantitative susceptibility mapping; RRMS, relapsing-remitting multiple sclerosis; WM, white matter. Source: Chen et al, Radiology 2014;271:183–192.
chronic nonenhancing) (Figs. 12 and 13). This MS lesion susceptibility time course is consistent with the no-phase-variation on the 2.5y follow-up of nonenhancing MS lesions seen in another study (215), and with the rapid increase of off-resonance frequency observed in acute enhancing lesions in a third study (216). Investigations are ongoing to connect susceptibility time course and MS cellular activities. QSM may constitute an important new biomarker for the inflammatory and neurodegenerative activities in MS.

Initial Results in Aorta, Breast, Extremity, and Kidney

QSM applications beyond the brain are also under active development (Fig. 14). The susceptibility values from phase data of the aortic arch during a Gd bolus passage may provide quantitative contrast-enhanced MRA (31) (Supp. Fig. S5). QSM is feasible for applications in other body parts including the breast, extremity, and abdomen (liver and kidney) for studying hemorrhage, metabolic oxygen consumption, mineral distribution, and contrast agent kinetics (96).

QSM of Tissue Complexity: Multiple Species and Microstructures

QSM techniques have started to proliferate, an indication that QSM is a fertile field for innovation. This review so far has focused on modeling a voxel of tissue with a scalar susceptibility. Here we briefly survey investigations to model MRI signal with tissue complexity: multiple species of different chemical shifts, subvoxel structures, and molecular structures.

Nonlinear Phase Behavior of Multiple Spectral Species, Long TE, Large Voxel

The signal model in Eq. [5] may be regarded as a first order (linear temporal phase evolution) approximation, which may be good enough for many brain applications. For imaging other body parts, there may be signal contribution from proton sources other than free water $w(r)$, such as fat $f(r)$ with chemical shift (characterized by a constant frequency offset $\omega \sim -3.4$ ppm). Eq. [14] can be generalized to account for the chemical shift effects on signal phase (217,218).

$$\omega, b, x, w, f = \arg\min_{b, x, w, f} \sum |s_j - (w + f) e^{-i\omega T_E} \rho e^{-i(d x + b) \omega T_E} |^2 + R(b, x, w, f).$$

FIG. 13. Time course of susceptibilities of multiple sclerosis lesions. The susceptibility time course may provide new insight into pathophysiologic features of MS lesions (23 patients with 162 lesions): Magnetic susceptibility of MS lesion increases rapidly as it changes from enhanced to nonenhanced, attains a high-susceptibility value relative to NAWM during its initial few years (approximately 4 years), and gradually dissipates back to susceptibility similar to that of NAWM as it ages. The graphs depict lesion susceptibility values (relative to NAWM) at various ages in QSM1 performed at a first time point (top) and in QSM2 at a second time point (bottom). Red points in QSM1 denote acute enhancing lesions at lesion age $= 0$ year; follow-up presented as green points in QSM2 demonstrated a substantial increase in susceptibility. Blue lines represent average susceptibilities of nonenhanced lesions in the age groups of 0 to 2, 2 to 4, 6 to 8, and 8 to 10 years and enhancing lesions. QSM, quantitative susceptibility mapping; MS, relapsing-remitting multiple sclerosis; NAWM, normal appearing white matter. Source: Chen et al, Radiology 2014;271:183–192.

FIG. 14. Quantitative susceptibility mapping applications in the breast and liver. (i) Left image is a mammogram and right image is the corresponding QSM (minimal intensity project through the 3D volume) of a breast in a female patient with three calcified nodules (arrow on QSM). Fatty tissues in the breast appear less diamagnetic compared to the gland. (ii) QSM and R2* images of a liver are shown in the left and right, respectively. Hepatic vein and subcutaneous fat (white arrows in left) appear paramagnetic. The susceptibility difference between the hepatic vein (white arrow) and the aortic artery (black arrow) are 0.53 ppm. 3D, three dimensional; QSM, quantitative susceptibility mapping.
Note that the signal phase from a voxel is now nonlinear in its temporal evolution. Initial results in solving Eq. [16] are very encouraging, promising to extend QSM to body parts with fat (Fig. 14). The approximation in Eq. [5] works very well in most imaging situations but may break down in the presence of unusually strong susceptibility sources, long TEs, large voxels, or a combination of these factors. We may need to include higher-order terms in the evaluation of the exponential and include contributions from the neighboring voxels using an accurate voxel sensitivity function (44,222). These complications lead to a voxel signal phase that varies nonlinearly with TE.

Signal Behavior with Subvoxel Structure

There is growing interest in modeling tissue microstructure using MRI (215,223–231). Subvoxel structures may be characterized as gradients and higher-order spatial derivatives in spin density and magnetic field (232). These violations of the smoothness assumption in digitizing Eq. [2] result in voxel signal phases with nonlinearly temporal evolutions. More useful models may include specific geometries for the underlying tissue microstructure such as solid or hollow cylinders for capillaries, fibers, and other linear microstructure (Supp. Fig. S6), also leading to phase nonlinear in time (225,227,233). Microstructures may be considered as static and observer water as undergoing rapid random motion. The ergodic hypothesis may be assumed: the sum over the observer water path becomes the sum over the ensemble distribution that is proportional to spin density. Then, voxel signal may be modeled as the sum of the contributions from water protons inside magnetic microstructures or compartments ($\Omega_c$) within the voxel. An example compartment is the cylinder or generalized Lorentz model (225). When water exchange among compartments is small, the signal model is a simple extension of Eq. [5],

$$s(t) \sim \sum_c \sum_{r \in \Omega_c} m(r)e^{-i\omega_s(r)\mu t}$$ \[17\]

Here, for a given subvoxel compartment model, Maxwell’s Equations can be used to determine the field’s dependence on subvoxel structures ($h_c(r)$) such as their orientations and underlying molecular susceptibility anisotropies (225,227,233). With a sufficient number of measurements, the compartmental susceptibility may be estimated from the MRI signals:

$$\{x_c\} = \operatorname{arg\,min}_{\{x_c\}} \sum_j \left| s_j - \sum_c \sum_{r \in \Omega_c} m(r)e^{-i\omega_s(r)\mu t_j} \right|^2 + R(\{x_c\})$$ \[18\]

Susceptibility Tensor

The diamagnetic susceptibilities of anisotropic molecules (Supp. Fig. S6) must be described by recognizing the susceptibility in Eq. [2] as a tensor. If all types of anisotropic molecules are sufficiently smoothly distributed in the space, and the spatial dispersion of phase accruals is sufficiently small in a voxel—as assumed in Eq. [5]—then the corresponding digital form of Eq. [2] with tensor susceptibility can be used, forming the foundation for susceptibility tensor imaging (STI) (234). Group symmetry theory suggests that susceptibility anisotropy can only be observed in a voxel if and only if anisotropic molecules are arranged orderly on a macroscopic scale (235,236). The increased number of variables in STI requires acquisitions at many orientations (237), which may be reduced by using prior information obtained from diffusion tensor imaging (235,236). Similar to Eq. [17], subvoxel structures may be incorporated into the MRI signal equation, introducing phase nonlinear in time and other complexities (233). The most interesting biomaterial demonstrating susceptibility anisotropy may be myelin (107,238), and the assessment of myelin integrity using MRI remains an important unmet clinical need.

CONCLUSION

Magnetic susceptibility directly reflects the molecular electron cloud behavior in the main magnetic field. Tissue susceptibility effects can be readily sensitized in MRI, for example using the widely available GRE sequence. Maxwell’s equations and the MRI signal equation can be used to quantitatively model the relationship between MRI signal and tissue susceptibility. Regularization is necessary to obtain a unique solution for determining the tissue susceptibility map from the acquired MRI signal, which is an ill-posed problem due to the lack of MRI signal in the background and the zeroes in the dipole kernel. The current status of QSM is very encouraging. The first order solution of QSM can be robustly obtained using physically meaningful regularizations, including the Bayesian approach. QSM has promising clinical and scientific applications that involve large susceptibility changes by hemoglobin, ferritin, calcification, and contrast agents. The investigations of higher order solutions have also been initiated, including studies of important magnetic anisotropies and tissue microstructures.

ACKNOWLEDGMENTS

We thank the members and collaborators of Professor Wang’s lab: Ludovic de Rochefort, Jing Liu, Dong Zhou, Bryan Kressler, Cynthia Wisnieff, Bo Xu, Rebecca Cramer, Mitchell Cooper, Shuai Wang, Shuo Wang, Yan Wen, Alexey Dimov, Jingwei Zhang, Sarah Eskreis-Winkler, Kofi Deh, Pascal Spincemaille, Shixing Chang, Huan Tan, Pottumarthi Prasad, Robert Edelman, Weiwei Chen, Susan Gauthier, Ajay Gupta, Toshihito Hira, Xue-mei Huang, Shingo Kakeda, Brian Kopell, Yukunori Kornogi, Christian Langkammer, Min Lou, Thanh Nguyen, David Pitt, Martin Prince, Stefan Ropele, and John Tsouris.

We also thank the following QSM developers, who have generously contributed to sources codes and experimental validations: Elfar Adalsteinsson, Berkin Bilgic, Richard Bowtell, Jeff Duyn, E. Mark Haacke, Wei Li, Chunlei Liu, Saifeng Liu, Jürgen Reichenbach, Ferdinand Schweser, Karin Shmueli, and Samuel Wharton.
REFERENCES

1. Wang Y. Principles of Magnetic Resonance Imaging: physics concepts, pulse sequences & biomedical applications. 2012. Available at: www.createspace.com/4001776. Accessed December 1, 2013.

2. de Crespigny AJ, Roberts TP, Kucharzyk J, Moseley ME. Improved sensitivity to magnetic susceptibility contrast. Magn Reson Med 1993;30:135–137.

3. Haacke EM, Xu Y, Cheng YC, Reichenbach JR. Susceptibility weighted imaging (SWI). Magn Reson Med 2004;52:612–618.

4. Haacke EM, Reichenbach J. Susceptibility weighted imaging in MRI: basic concepts and clinical applications. Hoboken, NJ: Wiley-Blackwell; 2011.

5. Jackson JD. Classical electrodynamics, 3rd ed. Hoboken, NJ: John Wiley and Son; 1999. p. 184–188.

6. Young JR, Khenia S, Thomas DG, Davis CH, Gadian DG, Cox IJ, Ross BD, Bydder GM. Clinical magnetic susceptibility mapping of the brain. J Comput Assist Tomogr 1987;11:2–6.

7. Li L, Leigh JS. Quantifying arbitrary magnetic susceptibility distributions with MR. Magn Reson Med 2004;51:1077–1082.

8. Mahdi K, Wlodarczyk W, Lange T, Scholz K, Jordan A, Wust P. Quantitative mapping of magnetic fluid distributions by means of MR susceptibility. In Proceedings of the 9th Annual Meeting of ISMRM, Glasgow, Scotland, UK, 2001. p. 797.

9. Haacke EM, Cheng NY, House MJ, Liu Q, Neelavalli J, Oggi RJ, Khan A, Ayaz M, Kirsch W, Oehanes A. Imaging iron stores in the brain using magnetic resonance imaging. Magn Reson Imaging 2005;23:112–125.

10. Shmueli K, de Zwart JA, van Gelderen P, Li TQ, Dodd SJ, Duyan JH. Magnetic susceptibility mapping of brain tissue in vivo using MRI phase data. Magn Reson Med 2009;62:1510–1522.

11. de Rochefort L, Brown R, Prince MR, Wang Y. Quantitative MR susceptibility mapping using piece-wise constant regularized inversion of the magnetic field. Magn Reson Med 2008;60:1003–1009.

12. Kressler B, de Rochefort L, Spincemaille P, Liu T, Wang Y. Estimation of sparse magnetic susceptibility distributions from MRI using non-linear regularization. In Proceedings of the 16th Annual Meeting of ISMRM, Toronto, Canada, 2008. p. 1514.

13. Yeo DT, Fessler JA, Kim B. Motion robust magnetic susceptibility and field inhomogeneity estimation using regularized image reconstruction techniques for MRI. Med Image Comput Comput Assist Interv 2008;11:991–998.

14. Liu T, Spincemaille P, de Rochefort L, Kressler B, Wang Y. Calculation of susceptibility through multiple orientation sampling (COMOS): a method for conditioning the inverse problem from measured magnetic field maps to susceptibility source images. Magn Reson Med 2009;61:196–204.

15. Wang Y, de Rochefort L, Liu T, Kressler B. Magnetic source MRI: a new quantitative imaging of magnetic markers. Conf Proc IEEE Eng Med Biol Soc 2009;2009:53–56.

16. Morgan J, Inravunsadal P. Efficient solving for arbitrary susceptibility distributions with residual difference fields. In Proceedings of the 15th Annual ISMRM Meeting-ESMRMB, Berlin, Germany, 2007. p. 35.

17. de Rochefort L, Liu T, Kressler B, Liu J, Spincemaille P, Lebon V, Wu J, Wang Y. Quantitative susceptibility map reconstruction from MR phase data using bayesian regularization: validation and application to brain imaging. Magn Reson Med 2010;63:204–206.

18. Kressler B, de Rochefort L, Spincemaille P, Liu T, Wang Y. Estimation of sparse magnetic susceptibility distributions from MRI using non-linear regularization. In Proceedings of the 16th Annual Meeting of ISMRM, Toronto, Canada, 2008. p. 1514.

19. Liu J, Liu T, de Rochefort L, et al. Morphology enabled dipole inversion for quantitative susceptibility mapping using structural consistency between the magnitude image and the susceptibility map. Neuroimage 2012;59:2560–2568.

20. Liu T, Wissief C, Lou M, Chen W, Spincemaille P, Wang Y. Nonlinear formulation of the magnetic field to source relationship for robust quantitative susceptibility mapping. Magn Reson Med 2013;69:467–476.

21. Kressler B, de Rochefort L, Liu T, Spincemaille P, Jiang Q, Wang Y. Nonlinear regularisation for per voxel estimation of magnetic susceptibility distributions from MRI field maps. IEEE Trans Med Imaging 2010;29:273–281.

22. Wharton S, Schafer A, Bowtew R. Susceptibility mapping in the human brain using threshold-based k-space division. Magn Reson Med 2010;63:1292–1304.

23. Li W, Wu B, Liu C. Quantitative susceptibility mapping of human brain reflects spatial variation in tissue composition. Neuroimage 2011;55:1645–1656.

24. Chen Z, Calhoun V. Computed inverse resonance imaging for magnetic susceptibility map reconstruction. J Comput Assist Tomogr 2012:26:265–274.

25. Scherzer F, Sommer K, Deistung A, Reichenbach JR. Quantitative susceptibility mapping for investigating subtle susceptibility variations in the human brain. Neuroimage 2012;62:2093–2100.

26. Scherzer F, Deistung A, Sommer K, Reichenbach JR. Toward online reconstruction of quantitative susceptibility maps: superfast dipole inversion. Magn Reson Med 2013;69:1582–1594.

27. Wu B, Li W, Guidon A, Liu C. Whole brain susceptibility mapping using compressed sensing. Magn Reson Med 2012;67:137–147.

28. Bilgic B, Fan AP, Polimeni JR, Cauley SF, Biancardi M, Adalsteinsson E, Wald LL, Setsompop K. Fast quantitative susceptibility mapping with L1-regularization and automatic parameter selection. Magn Reson Med 2014;72:1444–1459.

29. Bilgic B, Chatnuntawech I, Fan AP, Setsompop K, Cauley SF, Wald LL, Adalsteinsson E. Fast image reconstruction with L2-regularization. J Magn Reson Imaging 2014;40:181–191.

30. Tang J, Liu S, Neelavalli V, Cheng YC, Buch S, Haacke EM. Improving susceptibility mapping using a threshold-based k-space/image domain iterative reconstruction approach. Magn Reson Med 2013;69:1396–1407.

31. de Rochefort L, Nguyen T, Brown K, Spincemaille P, Choi G, Weisfisz J, Prince MR, Wang Y. In vivo quantification of contrast agent concentration using the induced magnetic field for time-resolved arterial input function measurement with MRI. Med Phys 2008;35:5328–5339.

32. Lambe WJ. Internal diamagnetic fields. Phys Rev 1941;60:817–819.

33. Ramsey NF. Magnetic shielding of nuclei in molecules. Phys Rev 1950;78:5.

34. Schindler M, Kutzelnigg W. Theory of magnetic-susceptibilities and NMR chemical-shifts in terms of localized quantities. Ill. Application to Hydrocarbons and Other Organic-Molecules. J Am Chem Soc 1983;105:1360–1370.

35. Duyan J. MR susceptibility imaging. J Magn Reson Imaging 2013;22:198–207.

36. Lauffer RB. Paramagnetic metal complexes as water proton relaxation agents for NMR imaging: theory and design. Chem Rev 1987;87:901–927.

37. Hahn EL. Spin echoes. Phys Rev 1950;80:580–594.

38. Bloembergen N, Morgan LO. Proton relaxation times in paramagnetic solutions. effects of electron spin relaxation. J Chem Phys 1961;34:8.

39. Solomon I. Relaxation processes in a system of two spins. Phys Rev 1955;99:559–565.

40. Yahlonisky DA, Haacke EM. Theory of NMR signal behavior in magnetically inhomogeneous tissues: the static dephasing regime. Magn Reson Med 1994;32:749–761.

41. Jensen JH, Chandra K, Ramanai A, Lu H, Johnson G, Lee SP, Kacynski K, Helpem Jr, J Magn Reson Imaging 2006;35:1350–1361.

42. Roemer PB, Edelstein WA, Hayes CE, Souza SP, Mueller GM. The NMR phased array. Magn Reson Med 1990;16:192–225.

43. Pruessmann KP, Weiger M, Scheidegger MB, Borsiger P. SENSE: sensitivity encoding for fast MRI. Magn Reson Med 1999;42:952–962.

44. Parker DL, Du YP, Davis WL. The voxel sensitivity function in Fourier transform imaging: applications to magnetic resonance angiography. Magn Reson Med 1995;33:156–162.

45. Tyler DJ, Robson MD, Henkelman RM, Young JR, Bydder GM. Magnetic resonance imaging with ultrashort TE (UTE) PULSE sequences: technical considerations. J Magn Reson Imaging 2007;25:279–289.

46. Robson MD, Gatehouse PD, Bydder M, Bydder GM. Magnetic resonance: an introduction to ultrashort TE (UTE) Imaging. J Comput Assist Tomogr 2003;27:825–846.

47. Weiger M, Pruessmann KP, Hennel F. MRI with zero echo time: hard versus sweep pulse excitation. Magn Reson Med 2011;66:379–389.

48. Xu B, Liu T, Spincemaille P, Prince M, Wang Y. Flow compensated quantitative susceptibility mapping for venous oxygenation imaging. Magn Reson Med 2014;72:439–445.

49. Wu B, Li W, Avram A, Liu C. Whole brain susceptibility mapping using compressed sensing. Magn Reson Med 2012;67:137–147.

50. Xu B, Liu T, Spincemaille P, Thimmappa N, Prince MR, Wang Y. Dynamic quantitative susceptibility mapping for contrast agent concentration. In Proceedings of the 21st Annual Meeting of ISMRM, Salt Lake City, Utah, USA, 2013. p. 3847.
51. Lim IA, Li X, Jones CK, Farrell JA, Vikram DS, van Zijl PC. Quantitative magnetic susceptibility mapping without phase unwrapping using WASSR. Neuroimage 2014;84:265–279.
52. Noceuld J, Wright SJ. Numerical optimization. New York: Springer; 2006. pp. xxiii, 664.
53. Pei M, Nguyen TD, Thimmapura ND, Salustri C, Dong F, Cooper MA, Li J, Prince MR, Wang Y. Algorithm for fast monoeponential fitting based on auto-regression on linear operations (ARLO) of data. Magn Reson Med 2014. doi: 10.1002/mrm.25137.
54. Bernstein MA, Grgic M, Bronsan TJ, Pelc NJ. Reconstructions of phase contrast, phased array multicoil data. Magn Reson Med 1994;32:330–344.
55. Thunberg P, Karlsson M, Wigstrom L. Comparison of different methods for forming phase-contrast images obtained with multiple coils. Magn Reson Imaging 2005;23:795–799.
56. Liu K, Liu TT, Bydder M. Optimal phase difference reconstruction: comparison of two methods. Magn Reson Imaging 2008;26:142–145.
57. Robinson S, Grabner G, Witoszynskyj S, Trattinig S. Combining phase images from multi-channel RF coils using 3D phase offset maps derived from a dual-echo scan. Magn Reson Med 2011;65:1638–1648.
58. Parker DL, Payne A, Todd N, Hadley JR. Phase reconstruction from Fourier-based method. NMR Biomed 2011;54:2789–2807.
59. Robinson S, Grabner G, Witoszynskyj S, Trattinig S. Combining phase images from multi-channel RF coils using 3D phase offset maps derived from a dual-echo scan. Magn Reson Med 2011;65:1638–1648.
60. Parkin DL, Payne A, Todd N, Hadley JR. Phase reconstruction from Fourier-based method. NMR Biomed 2011;54:2789–2807.
61. Schofield MA, Zhu Y. Fast phase unwrapping algorithm for interferometric applications. Opt Lett 2003;28:1194–1196.
62. Li W, Avram AV, Wu B, Xiao X, Liu C. Integrated Laplacian-based phase unwrapping and background phase removal for quantitative susceptibility mapping. NMR Biomed 2014;27:219–227.
63. Xu W, Cumming I. A region-growing algorithm for InSAR phase unwrapping. IEEE Trans Geosci Remote Sens 1999;37:1572–1578.
64. Witoszynskyj S, Rauscher A, Reichenbach JR, Barth M. Phase unwrapping of MR images using Phi UN—a fast and robust region growing algorithm. Med Image Anal 2009;13:257–268.
65. Cusack R, Papadakis N. New robust 3-D phase unwrapping algorithms: application to magnetic field mapping and undistorting echo-planar images. Neuroimage 2002;16:754–764.
66. See JK, Woe EF, Katscher S, Wang Y. Electro-magnetic tissue properties MRI. Ammari H, editor. London, UK: Imperial College Press; 2014.
67. Langham MC, Magland JF, Floyd TF, Wehrli FW. Retrospective correction for induced magnetic field inhomogeneity in measurements of large-vessel hemoglobin oxygen saturation by MR susceptibility. Magn Reson Med 2009;61:626–633.
68. Wang Y, Yu Y, Li D, Bae KT, Brown JJ, Lin W, Haacke EM. Artery and vein separation using susceptibility-dependent phase in contrast-enhanced MRA. J Magn Reson Imaging 2000;12:661–670.
69. Liu T, Khalidov I, de Rochefort L, Spincemaille P, Liu J, Tsouris AJ, Wang Y. A novel background field removal method for MRI using projection onto dipole fields (PDF). NMR Biomed 2011;24:1129–1136.
70. Schweser F, Deistung A, Reichenbach JR. Differentiation between diamagnetic and paramagnetic cerebral lesions based on magnetic susceptibility mapping. Med Phys 2010;37:5165–5178.
71. Bilge B, Pfefferbaum A, Rohlfing T, Sullivan EV, Adalsteinsson E. MRI estimates of brain iron concentration in normal aging using quantitative susceptibility mapping. Neuroimage 2012;59:2625–2635.
72. Schweser F, Deistung A, Reichenbach JR. Differentiation between diamagnetic and paramagnetic cerebral lesions based on magnetic susceptibility mapping. Med Phys 2010;37:5165–5178.
73. Schweser F, Deistung A, Reichenbach JR. Differentiation between diamagnetic and paramagnetic cerebral lesions based on magnetic susceptibility mapping. Med Phys 2010;37:5165–5178.
74. Schweser F, Deistung A, Reichenbach JR. Differentiation between diamagnetic and paramagnetic cerebral lesions based on magnetic susceptibility mapping. Med Phys 2010;37:5165–5178.
75. Schweser F, Deistung A, Reichenbach JR. Differentiation between diamagnetic and paramagnetic cerebral lesions based on magnetic susceptibility mapping. Med Phys 2010;37:5165–5178.
76. Schweser F, Deistung A, Reichenbach JR. Differentiation between diamagnetic and paramagnetic cerebral lesions based on magnetic susceptibility mapping. Med Phys 2010;37:5165–5178.
77. Schweser F, Deistung A, Reichenbach JR. Differentiation between diamagnetic and paramagnetic cerebral lesions based on magnetic susceptibility mapping. Med Phys 2010;37:5165–5178.
78. Schweser F, Deistung A, Reichenbach JR. Differentiation between diamagnetic and paramagnetic cerebral lesions based on magnetic susceptibility mapping. Med Phys 2010;37:5165–5178.
79. Schweser F, Deistung A, Reichenbach JR. Differentiation between diamagnetic and paramagnetic cerebral lesions based on magnetic susceptibility mapping. Med Phys 2010;37:5165–5178.
80. Schweser F, Deistung A, Reichenbach JR. Differentiation between diamagnetic and paramagnetic cerebral lesions based on magnetic susceptibility mapping. Med Phys 2010;37:5165–5178.
81. Schweser F, Deistung A, Reichenbach JR. Differentiation between diamagnetic and paramagnetic cerebral lesions based on magnetic susceptibility mapping. Med Phys 2010;37:5165–5178.
82. Schweser F, Deistung A, Reichenbach JR. Differentiation between diamagnetic and paramagnetic cerebral lesions based on magnetic susceptibility mapping. Med Phys 2010;37:5165–5178.
83. Schweser F, Deistung A, Reichenbach JR. Differentiation between diamagnetic and paramagnetic cerebral lesions based on magnetic susceptibility mapping. Med Phys 2010;37:5165–5178.
84. Schweser F, Deistung A, Reichenbach JR. Differentiation between diamagnetic and paramagnetic cerebral lesions based on magnetic susceptibility mapping. Med Phys 2010;37:5165–5178.
85. Schweser F, Deistung A, Reichenbach JR. Differentiation between diamagnetic and paramagnetic cerebral lesions based on magnetic susceptibility mapping. Med Phys 2010;37:5165–5178.
86. Schweser F, Deistung A, Reichenbach JR. Differentiation between diamagnetic and paramagnetic cerebral lesions based on magnetic susceptibility mapping. Med Phys 2010;37:5165–5178.
87. Schweser F, Deistung A, Reichenbach JR. Differentiation between diamagnetic and paramagnetic cerebral lesions based on magnetic susceptibility mapping. Med Phys 2010;37:5165–5178.
88. Schweser F, Deistung A, Reichenbach JR. Differentiation between diamagnetic and paramagnetic cerebral lesions based on magnetic susceptibility mapping. Med Phys 2010;37:5165–5178.
89. Schweser F, Deistung A, Reichenbach JR. Differentiation between diamagnetic and paramagnetic cerebral lesions based on magnetic susceptibility mapping. Med Phys 2010;37:5165–5178.
90. Schweser F, Deistung A, Reichenbach JR. Differentiation between diamagnetic and paramagnetic cerebral lesions based on magnetic susceptibility mapping. Med Phys 2010;37:5165–5178.
91. Schweser F, Deistung A, Reichenbach JR. Differentiation between diamagnetic and paramagnetic cerebral lesions based on magnetic susceptibility mapping. Med Phys 2010;37:5165–5178.
92. Schweser F, Deistung A, Reichenbach JR. Differentiation between diamagnetic and paramagnetic cerebral lesions based on magnetic susceptibility mapping. Med Phys 2010;37:5165–5178.
93. Schweser F, Deistung A, Reichenbach JR. Differentiation between diamagnetic and paramagnetic cerebral lesions based on magnetic susceptibility mapping. Med Phys 2010;37:5165–5178.
103. Huisman TA. Intracranial hemorrhage: ultrasound, CT and MRI findings. Eur Radiol 2005;15:434–440.
104. Makariou E, Patsalides AD. Intracranial calcifications. Appl Radiol 2009;38:48–54.
105. Shental N, Bar-Hillel A, Hertz T, Weinshall D. Computing Gaussian mixture models with EM using side-information. Jerusalem, Israel: Hebrew University of Jerusalem; 2003.
106. Deistung A, Schewe F, Wiestler B, et al. Quantitative susceptibility mapping differentiates between blood depositions and calcifications in patients with glioblastoma. PloS One 2013;8:e57924.
107. Liu C, Li W, Johnson GA, Wu B. High-field (9.4 T) MRI of brain dysmyelination by quantitative mapping of magnetic susceptibility. Neuroimage 2011;56:930–938.
108. Bradley WG, Jr. MR appearance of hemorrhage in the brain. Radiology 1999;189:15–26.
109. Heier LA, Amster JL, Zimmerman RD, et al. Focal recurrent hemorrhage on magnetic resonance at 0.5 Tesla. An aid to the diagnosis of cryptic cerebral vascular malformations. Acta Radiol Suppl 1986;369:113–115.
110. Zimmerman RD, Heier LA, Snow RB, Liu DP, Kelly AB, Deck MD. Acute intracranial hemorrhage: intensity changes on sequential MR scans at 0.5 T. AJR Am J Roentgenol 1986;150:651–661.
111. Liu T, Sun Y, Wang K, Liu M, Chen L, Spinicamaille P, Wang Y. Cerebral microbleeds: burden assessment by using quantitative susceptibility mapping. Radiology 2012;262:269–278.
112. Kidwell CS, Chalela JA, Saver JL, et al. Comparison of MRI and CT for detection of acute intracerebral hemorrhage. JAMA 2004;292:1823–1830.
113. Fleisch JR, Schellinger PD, Gass A, et al. Stroke magnetic resonance imaging is accurate in hyperacute intracerebral hemorrhage: a multicenter study on the validity of stroke imaging. Stroke 2004;35:502–506.
114. Broderick JP, Brott TG, Duldner JE, Tomsick T, Huster G. Volume of mortality. Stroke 1993;24:987–993.
115. Davis SM, Broderick J, Hennerici M, Brun NC, Diringer MN, Mayer JA. Increased iron-related MRI contrast in the substantia nigra in Parkinson’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis. Adv PharmacoSc 2011;38:72872.
116. Crichton RR, Dettner DT, Ward RJ. Brain iron metabolism and its perturbation in neurological disorders. J Neural Transm 2011;118:301–314.
117. Giese WK, Nichol H, Liu S, Cheng YC, Haacke EM. Measuring iron in the brain using quantitative susceptibility mapping and x-ray fluorescence imaging. Neuroimage 2011;57:687–719.
118. Oshiro S, Morioza MS, Kikuchi M. Disturbance of iron metabolism in Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis. Adv Pharmacol Sci 2011;38:257611.
119. Williams R, Buchheit CL, Berman NE, LeVine SM. Pathogenic implications of iron accumulation in multiple sclerosis. J Neurochem 2012;129:7:25–75.
120. Wanger SM, Broderick J, Hennrici M, Brun NC, Diringer MN, Mayer JA, Begtrup K, Steiner T. Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage. Neurology 2006:66:1175–1181.
121. Blohs J, Deistung A, Schewe F, Grandjean J, Dominietto M, Waschek C, Nitsch RM, Knuessel I, Reichenbach JR, Rudin M. Detection of cerebral microbleeds with quantitative susceptibility mapping in the ArcAbeta mouse model of cerebral amyloidosis. J Cereb Blood Flow Metab 2011;31:2282–2292.
122. Wang S, Liu M, Liu T, Cui D, Chen X, Wang Y. Hematoma volume measurement in gradient echo MRI using quantitative susceptibility mapping. Stroke 2013;44:2315–2317.
123. Andre B, Nellavalli J, Cheng YC. Susceptibility mapping as a means to visualize veins and quantify oxygen saturation. J Magn Reson Imaging 2010;32:663–676.
124. Fan AP, Bilicic B, Gagnon L, Witzel T, Bhat H, Rosen BR, Adalsteinsson E. Quantitative measurement of cerebral physiology using respiratory-calibrated MRI. Neuroimage 2012;60:582–591.
125. Gauthier CJ, Hoge RD. Magnetic resonance imaging of resting OEF and CMRO2(2) using a generalized calibration model for hypercapnia and hypoxia. Neuroimage 2012;60:1212–1225.
126. Wise RG, Ransom AD, Stone AJ, Murphy K. Measurement of OEF and absolute CMRO2: MRI-based methods using interleaved and combined hypercapnia and hypoxia. Neuroimage 2013;83:135–147.
127. Zhang J, Pei M, Liu T, Gupta A, Wissier C, Sanelli PC, Spinicamaille P, Wang Y. Quantitative susceptibility mapping (QSM) for high resolution quantitative cerebral metabolic rate of oxygen. In Proceedings of the 21st Annual Meeting of ISMM, Salt Lake City, Utah, USA, 2013. p. 3334.
128. Moos T, Morgan EH. The metabolism of neuronal iron and its pathogenic role in neurological disease: review. Ann NY Acad Sci 2004;1012:14–26.
129. Lee DW, Andersen JK, Kaur D. Iron dysregulation and neurodegeneration: the molecular connection. Mol Interv 2006;6:89–97.
130. Zecca L, Youdim MB, Riederer P, Connor JR, Crichton RR. Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci 2006;7:863–873.
131. Crichton RR. Iron metabolism: from molecular mechanisms to clinical concomitances. Chichester, UK: John Wiley & Sons; 2009. pp. xx, 461.
132. Lim IA, Faria AV, Li X, Hsu JT, Airan RD, Mori S, van Zijl PC. Human brain atlas for automated region of interest selection in quantitative susceptibility mapping: Application to determine iron content in deep gray matter structures. Neuroimage 2013;82:449–469.
133. Zhang W, Nichol H, Liu S, Cheng YC, Haacke EM. Measuring iron in the brain using quantitative susceptibility mapping and x-ray fluorescence imaging. Neuroimage 2011;57:687–719.
134. Oshiro S, Morioza MS, Kikuchi M. Disturbance of iron metabolism in Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis. Adv Pharmacol Sci 2011;38:72872.
135. Crichton RR, Dettner DT, Ward RJ. Brain iron metabolism and its perturbation in neurological disorders. J Neural Transm 2011;118:301–314.
136. Nunez MT, Urrutia P, Mena N, Aguiarre P, Tapia V, Salazar J. Iron toxicity in neurodegeneration. Biometals 2012;25:761–776.
137. Williams R, Buchheit CL, Berman NE, LeVine SM. Pathogenic implications of iron accumulation in multiple sclerosis. J Neurochem 2012;129:7:25–75.
138. Dettner DT, Wells FR, Agid F, Agid Y, Lees AJ, Jenner P, Marsden CD. Increased iron content in postmortem parkinsonian brain. Lancet 1987;2:1219–1220.
139. Riederer P, Sojic E, Rausch WD, Schmidt B, Reynolds GP, Jellinger K, Youdim MB. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem 1989;52:515–520.
140. Hirsch EC, Brandel JP, Galle P, Javy-Agid F, Agid Y. Iron and aluminum increase in the substantia nigra of patients with Parkinson’s disease: an x-ray microanalysis. J Neurochem 1991;56:446–451.
141. Oakley AE, Collingwood JD, Dobson J, Love G, Perrott HR, Edwardson JA, Elstner M, Morris CM. Individual dopaminergic neuroinnervation shows increased iron levels in Parkinson disease. Neurology 2007;68:1820–1825.
142. Lotfipour AK, Wharton S, Schwarz ST, Gontu V, Schafer A, Peters AM, Bowtell RW, Auer DP, Gowland PA, Bajaj NP. High resolution magnetic susceptibility mapping of the substantia nigra in Parkinson’s disease: J Magn Reson Imaging 2012;35:448–55.
143. Ulla M, Bonny JM, Ouchchane I, Rieu I, Claise B, Durif F. Is R2* a new MRI biomarker for the progression of Parkinson’s disease? A longitudinal follow-up. PloS One 2013;8:e57904.
144. Youdim MB, Ben-Shachar D, Riederer P. Iron in brain function and dysfunction with emphasis on Parkinson’s disease. Eur Neurol 1991;31 suppl (1):34–40.
145. Jomova K, Vondraková D, Lawson M, Valkó M. Metals, oxidative stress and neurodegenerative disorders. Mol Cell Biochem 2010:345:91–104.
146. Hashimoto M, Takeda A, Hsu LJ, Takenouchi T, Masiha E. Role of cytochrome c as a stimulator of alpha-synuclein aggregation in Lewy body disease. J Biol Chem 1999;274:28494–28495.
147. Li W, Jiang H, Song N, Xie J. Oxidative stress partially contributes to iron-induced alpha-synuclein aggregation in SK-N-SH cells. Neurrotox Res 2011;19:435–442.
148. Ornidge RJ, Goell RJ, Deniau JC, Knight RA, Helpern JA. Assessment of relative brain iron concentrations using T2-weighted and T2*-weighted MRI at 3 Tesla. Magn Reson Med 1994;32:335–341.
149. Horn JD, Ornidge RJ, Brown GG, Deniau JC, Buderer NM, Helpern JA. Increased iron-related MRI contrast in the substantia nigra in Parkinson’s disease. Neuroimage 1995;31:suppl (1):34–40.
192. Roberts TP. Physiologic measurements by contrast-enhanced MR imaging: expectations and limitations. J Magn Reson Imaging 1997;7:82–90.

193. Schabel MC, Parker DL. Uncertainty and bias in contrast concentration measurements using spoiled gradient echo pulse sequences. Phys Med Biol 2008;53:2345–2373.

194. Stanisz GJ, Henkelman RM. GD-DTPA relativity depends on macromolecular content. Magn Reson Med 2000;44:665–670.

195. Bowen CV, Zhang X, Saah G, Gareau PJ, Rutt BK. Application of the static dephasing regime theory to superparamagnetic iron-oxide loaded cells. Magn Reson Med 2002;48:52–61.

196. Terrone E, Genniatti Grich S, Belfiore S, Biancone L, Cabella C, Esposito G, Mananza AD, Aime S. Effect of the intracellular localization of a Gd-based imaging probe on the relaxation enhancement of water protons. Magn Reson Med 2006;55:491–497.

197. Zurkiya O, Chan AW, Hu X. MagA is sufficient for producing magnetic nanoparticles in mammalian cells, making it an MRI reporter. Magn Reson Med 2008;59:1225–1231.

198. Lauffer RB. Magnetic resonance contrast media: principles and progress. Magn Reson Q 1990;6:65–84.

199. Kirsch JE. Basic principles of magnetic resonance contrast agents. Top Magn Reson Imaging 1991;3:1–18.

200. Toth E, Helm L, Merbach A. Relaxivity of MRI contrast agents. Contrast agents I. Topics in current chemistry, volume 221. Berlin, Germany: Springer-Verlag, 2002, p. 61–106.

201. Xu B, Spincemaille P, Chen G, Agrawal M, Nguyen TD, Prince MR, Wang Y. Fast 3D contrast enhanced MRI of the liver using temporal resolution acceleration with constrained evolution reconstruction. Magn Reson Med 2013;69:370–381.

202. Bonekamp D, Li X, Leighton R, Van Zijl PC, Barker PB. Optimized processing of quantitative susceptibility mapping-based gadolinium perfusion MRI: correction of bulk susceptibility effects and comparison of arterial input function selection from deltaR² and QSM data. In Proceedings of the 21st Annual Meeting of ISMRM, Salt Lake City, Utah, USA, 2013, p. 0585.

203. Hannoun K, Metcalf M, Carvajal L, Okuda DT, Srinivasan R, Vigneron D, Nelson SJ, Petletier D. Quantitative in vivo magnetic resonance imaging of multiple sclerosis at 7 Tesla with sensitivity to iron. Ann Neurol 2008;64:707–713.

204. Haacke EM, Makki M, Ge Y, et al. Characterizing iron deposition in multiple sclerosis lesions measured by susceptibility-weighted imaging. J Magn Reson Imaging 2009;29:537–544.

205. Hagemeier J, Heininen-Brown M, Poloni GU, et al. Iron deposition in multiple sclerosis: a quantitative 3T MRI study. Neurology 2011;77:1526–1532.

206. Haacke EM, Makki M, Ge Y, et al. Characterizing iron deposition in multiple sclerosis lesions using susceptibility weighted imaging filtered phase: a case control study. J Magn Reson Imaging 2012;36:73–83.

207. Eissa A, Lebel RM, Korzan JR, Zavodni AE, Warren KG, Catz I, Emery DJ, Willman AH. Detecting lesions in multiple sclerosis at 4.7 tesla using phase susceptibility-weighting and T2-weighting. J Magn Reson Imaging 2009;30:737–742.

208. Walsh AJ, Lebel RM, Eissa A, et al. Multiple sclerosis: validation of MR imaging for quantification and detection of iron. Radiology 2012;265:528–542.

209. Khalil M, Langkammer C, Ropele S, et al. Determinants of brain iron in multiple sclerosis: a quantitative 3T MRI study. Neurology 2011;77:1691–1697.

210. Habib CA, Liu M, Bawany N, Garbern I, Krumbein I, Mentzel HJ. Tracking iron accumulation in the deep gray matter of patients with multiple sclerosis versus healthy controls. AJNR Am J Neuroradiol 2012;33:252–258.

211. Yao B, Bagnato F, Matsuura E, Merkle H, van Gelderen P, Cantor FK, Duyn JH. Chronic multiple sclerosis lesions: characterization with high-field-strength MR imaging. Radiology 2012;262:206–215.

212. Bagnato F, Hamster S, Yao B, van Gelderen P, Merkle H, Cantor FK, Lassmann H, Duyn JH. Tracking iron in multiple sclerosis: a combined imaging and histopathological study at 7 Tesla. Brain 2011;134:3602–3615.

213. Langkammer C, Liu T, Khalil M, Eizinger C, Johna M, Fuchs S, Farekas F, Wang Y, Ropele S. Quantitative susceptibility mapping in multiple sclerosis. Radiology 2013;267:551–559.

214. Chen W, Gauthier SA, Gupta A, Comunale J, Liu T, Wang S, Pei M, Pitt D, Wang Y. Quantitative susceptibility mapping of multiple sclerosis lesions at various ages. Radiology 2014;271:183–192.

215. Yablonskii DA, Luo J, Sukstanskii AL, Iyer A, Cross AH, Biophysical methods of magnetic resonance imaging in multiple sclerosis. Proc Natl Acad Sci U S A 2012;109:14212–14217.

216. Wintermark M, Hernandez Torres E, Vavassour IM, Moore GR, Laule C, Mackay AL, Li DK, Tsudo A, Rauscher A. Magnetic resonance frequency shifts during acute MS lesion formation. Neurology 2013;81:211–218.

217. Dixon WT. Simple proton spectroscopic imaging. Radiology 1984;153:189–194.

218. Reeder SB, Tran Z, Yu H, Pineo AR, Gold GE, Markl M, Peltz NL. Multicoil Dixon chemical species separation with an iterative least-squares estimation method. Magn Reson Med 2004;51:35–45.

219. Yu H, Reeder SB, Shimakawa A, Brittain JH, Peltz NL. Field map estimation with a region growing scheme for iterative 3-point water-fat decomposition. Magn Reson Med 2005;54:1032–1039.

220. Hernando D, Haldar JP, Sutton BP, Ma J, Kellman P, Liang ZP. Joint estimation of water/fat images and field inhomogeneity map. Magn Reson Med 2008;59:571–580.

221. Hernando D, Kellman P, Haldar JP, Liang ZP. Robust water-fat separation in the presence of large field inhomogeneities using a graph cut algorithm. Magn Reson Med 2010;63:79–90.

222. Yablonskii DA, Sukstanskii AL, Luo J, Wang X. Voxel spread function method for correction of magnetic field inhomogeneity effects in quantitative gradient-echo-based MRI. Magn Reson Med 2013;70:1283–1292.

223. Duyn JH, van Gelderen P, Li TQ, de Zwart JA, Koresky AP, Fukunaga M, High-field MRI of brain cortical substructure based on signal phase. Proc Natl Acad Sci U S A 2007;104:11796–11801.

224. Zhong K, Leopold J, van Elferdelt D, Speck O. The molecular basis for gray and white matter contrast in phase imaging. Neuroimage 2008;40:1561–1566.

225. He X, Yablonskii DA, Biophysical mechanisms of phase contrast in gradient echo MRI. Proc Natl Acad Sci U S A 2009;106:13558–13563.

226. van Gelderen P, de Zwart JA, Lee J, Sati P, Reich DS, Duyn JH. Non-exponential T2 decays in white matter. Magn Reson Med 2012;67:110–117.

227. Wharton S, Bowtell R. Fiber orientation-dependent white matter contrast in gradient echo MRI. Proc Natl Acad Sci U S A 2012;109:18559–18564.

228. Sati P, van Gelderen P, Silva AC, Reich DS, Merkle H, de Zwart JA, Duyn JH. Micro-compartment specific T2* relaxation in the brain. Neuroimage 2013;77:268–278.

229. Dibb R, Li W, Cofer G, Liu C. Microstructural origins of gadolinium-enhanced susceptibility contrast and anisotropy. Magn Reson Med 2014;72:1702–1711.

230. Liu C, Li W. Imaging neural architecture of the brain based on its multipole magnetic response. Neuroimage 2013;67:193–202.

231. Chen W, Foxley S, Miller KL. Detecting microstructural properties of white matter based on compartmentalization of magnetic susceptibility. Neuroimage 2013;76:1–9.

232. Bakker CJ, Seppenwoolde JH, Vincken KL. DphasefMRI. Magn Reson Med 2006;55:92–97.

233. Sukstanskii AL, Yablonskii DA. On the role of neuronal magnetic susceptibility and structure symmetry on gradient echo MR signal formation. Magn Reson Med 2014;71:345–353.

234. Liu C. Susceptibility tensor imaging. Magn Reson Med 2010;63:1471–1477.

235. Wisnieff C, Liu T, Spincemaille P, Wang S, Zhou D, Yang Y. Magnetic susceptibility anisotropy: cylindrical symmetry from macroscopically ordered anisotropic molecules and accuracy of MRI measurements using few orientations. Neuroimage 2013;70:363–376.

236. Li X, Vikram DS, Lim IA, Jones CK, Farrell JA, van Zijl PC. Mapping magnetic susceptibility anisotropies of white matter in vivo in the human brain at 7 T. Neuroimage 2012;62:314–330.

237. Liu C, Li W, Wu B, Jiang Y, Johnson GA. 3D fiber tractography with susceptibility tensor imaging. Neuroimage 2012;59:1290–1298.

238. Lee J, Shimueli F, Fukunaga M, van Gelderen P, Merkle H, Silva AC, Duyn JH. Sensitivity of MRI resonance frequency to the orientation of brain tissue microstructure. Proc Natl Acad Sci U S A 2010;107:5130–5135.